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One of the main treatments currently used in humans to ﬁght cancer is chemotherapy. A huge number of compounds with
antitumor activity are present in nature, and many of their derivatives are produced by microorganisms. However, the search for
new drugs still represents a main objective for cancer therapy, due to drug toxicity and resistance to multiple chemotherapeutic
drugs. In animal models, a short-time oral administration of dextran sulfate sodium (DSS) induces colitis, which exhibits several
clinical and histological features similar to ulcerative colitis (UC). However, the pathogenic factors responsible for DSS-induced
colitis and the subsequent colon cancer also remain unclear. We investigated the eﬀect of FR91, a standardized lysate of microbial
cells belonging to the Bacillus genus which has been previously shown to have signiﬁcant immunomodulatory eﬀects, against
intestinal inﬂammation. Colitis was induced in mice during 5 weeks by oral administration 2% (DSS). Morphological changes
in the colonic mucosa were evaluated by hematoxylin-eosin staining and immunohistochemistry methods. Adenocarcinoma and
cryptal cells of the dysplastic epithelium showed cathenin-β, MLH1, APC, and p53 expression, together with increased production
of IFN-γ. In our model, the optimal dose response was the 20% FR91 concentration, where no histological alterations or mild
DSS-induced lesions were observed. These results indicate that FR91 may act as a chemopreventive agent against inﬂammation in
mice DSS-induced colitis.
1.Introduction
Inﬂammatory bowel disease (IBD) is a group of chronic
conditions of the colon and small intestine, consisting of
Crohn’s disease (CD) and ulcerative colitis (UC), charac-
terized by acute pain, vomiting, and diarrhea symptoms
followed by remission [1]. A single etiology has not been
identiﬁed,butratherthepathogenesisofIBDisverycomplex
and involves the external environment, genetic makeup,
intestinal microbial ﬂora, and immune system [2]. Although
new and powerful medical treatments are available, many
are biological drugs or immunosuppressants, which are
associated with signiﬁcant side eﬀects, in particular infection
and increased risk of malignancy [3], and elevated costs
which require optimal medical treatment adjustment. As a
result, the need for predicting disease course and response
to therapy is essential. Major attempts have been made at
identifying clinical characteristics, concurrent medical ther-
apy, and serological and genetic markers as predictors of
response to biological agents. Only few reports exist on how
mucosal/tissue markers are capable of predicting clinical be-
haviour of the disease or its response to therapy [4].
Due to its ability of interfering with intestinal barrier
function and stimulating local and systemic inﬂammation,
dextran sodium sulfate (DSS) is often used as a mouse model
of colitis which can mimic clinical and histological features
of IBD with UC characteristics. Several animal models for
intestinal inﬂammation have been developed in recent years.
Most commonly, experimental colitis is induced by heparin-
like polysaccharide DSS because of its capacity of inducing2 Journal of Biomedicine and Biotechnology
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Figure 1: Experimental protocol for DSS-induced colitis/colon cancer in mice and the administration of FR91 at diﬀerent concentrations.
colonic lesions [5]. Okayasu et al. [6] showed that oral
administration of 5% of DSS in drinking water of BALB/c
mice was able to induce a chronic colitis after several cycles
of DSS. This study was followed by a report from Cooper
et al. [7] who induced chronic colitis by (a) 7 days of oral
DSS followed by 7 days of H2O (for 1, 2, and 3 cycles) and
(b) 7 days of oral DSS followed by 14 and 21 days of H2O.
The results of this study showed that chronic colitis induced
a f t e ro n l y7d a y so fD S Sm a ys e r v ea sau s e f u lm o d e lt os t u d y
the eﬀects of pharmacologic agents in human inﬂammatory
disease and mechanisms of perpetuation of inﬂammation
and gave an extensive description of histological lesions,
showing that the main histological changes consisted of focal
crypt loss, which was followed by signs of both acute and
chronic inﬂammation.
The present study aimed to investigate the eﬀect of FR-
91 on the attenuation of the chronic experimental colitis
induced by DSS in Swiss mice. Furthermore, we investigated
if the chronic phase was characterized by a regulation in the
expression of apoptotic genes and by a dysregulation of T
helper 1 (Th1)/T helper 2 (Th2) balance and how this would
relate to mucosal regeneration.
2.MaterialsandMethods
2.1. Animals. Twenty-six speciﬁc pathogen-free Swiss CD1
female mice (7 weeks old; Santiago de Compostela’s Uni-
versity Animal Breeding Core, Spain) were maintained (two
or three per cage) in isolator plastic cages with shavings
under standard laboratory conditions (sterilizable diet,
50% humidity, 23-24◦C temperature, and 12-h light/dark
cycle). All mice were quarantined 3 weeks after arrival and
then randomized by body weight into experimental and
control groups. All mice were permitted free access to a
commercial diet and treatment or normal drinking tap
water in individual bottles. All procedures conformed to
the guidelines established by the European Communities
Council Directive of 24 November 1986 (86/609/EEC) and
by the Spanish Royal Decree 1201/2005 for animal experi-
mentation and were approved by the Ethical Committee of
EBIOTEC.
2.2. Study Design. The design of the present study was
focused primarily on inducting colitis-associated dyspla-
sia and/or ulcerative hallmarks by administering synthetic
dextran sulfate sodium (DSS) to mice and then treating
them with diﬀerent FR91 (standardized lysate of microbial
cells belonging to the Bacillus genus) dilutions as shown in
Figure 1. At the age of 7 weeks, the animals were divided
into two control groups (1 and 2, n = 4e a c hg r o u p )a n d
three experimental groups (3–5, n = 6e a c hg r o u p ) .A l o n g
the entire experimental procedure, distilled water containing
diﬀerent FR91 dilutions (5% in group 3, 10% in 1 and 4, and
20% in 5) was administrated to the animals in groups 1, 3–
5. From the third week onwards, distilled water containing
20g/L (2%) synthetic dextran sulfate sodium (DSS; mol
mass 5000; D4911, Sigma-Aldrich; MO, USA) was also
administrated to animals of groups 2–5. For comparison,
control groups 1 and 2 received DSS or the FR91 treatment
alone, respectively, as untreated control. All mice were
sacriﬁced at the end of the experiment (8th week), at the age
of 15 weeks.
2.3. Induction of Colitis. Experimental colitis was induced to
mice of groups 2, 3, 4, and 5, by repeated administrations
of 2% (wt/vol; 20g/L) DSS in drinking tap water ad libitum
for ﬁve weeks. This dose was empirically reported to induce
moderate to severe colitis while minimize mortality in mice
[2]. None of the mice died before the termination of this
experiment study at day 50.
2.4. Tissue Preparation. Mice were deeply anesthetized with
ether and intracardially perfused with saline buﬀer and then
ﬁxed by 4% paraformaldehyde in 0.1M phosphate buﬀer
(pH 7.4). The entire colorectum (from colocecal junction to
the anal verge) was removed, measured, examined macro-
scopically, washed with saline buﬀer, and immediately ﬁxed
by immersion in the same ﬁxative for 48h. Part of the colon
was divided into three equal segments (proximal, middle,
and distal), and portions were determined under a dissecting
stereomicroscope (Leica, M125). Intestine portions were
cryoprotected with 30% sucrose in 0.1M phosphate buﬀer,
embedded in OCT compound (Tissue Tek, Torrance, CA),
and frozen with liquid-nitrogen-cooled isopentane. ParallelJournal of Biomedicine and Biotechnology 3
series of transverse sections of 14–16μm thick were obtained
on a cryostat (Starlet 2212, Bright, UK) and mounted on
Superfrost Plus (Menzel-Gl¨ aser) slides.
2.5. Histological Staining and Immunohistochemistry. Rou-
tine histological examination was performed on hema-
toxylin and eosin (H&E)-stained sections, where diﬀerent
morphological alterations that occur during inﬂammation-
associated colorectal carcinogenesis (such as cryp abscess,
mucosal dysplasia, adenomas, and adenocarcinomas), were
identiﬁed and diagnosed according to previous published
studies, see Keohane et al. [1]. To detect the expression of
colorectal histopathological markers such as Catenin-β, p53,
BCL-2, MLH1, and APC, we used immunohistochemical
techniques. The sections were pretreated with H2O2 to
eliminateendogenousperoxidase,rinsedtwiceinphosphate-
buﬀered saline (PBS) at pH 7.4 (10 minutes each), and
then sequentially treated with nonspeciﬁc binding blocked
solution (0.1M PBS containing 0.2% Tween 20 and 15%
normal goat serum from Dako; Glostrup, Denmark) for
1h, primary rabbit policlonal antibodies such as anti-
catenin-β, anti-p53, anti-BCL-2, anti-MLH1, and anti-APC
antibodies (rabbit antibodies that were aﬃnity puriﬁed from
rabbit antiserum by aﬃnity chromatography using mouse
epitope-speciﬁc immunogen; Bioworld Technology, MN,
USA; Cat. No. BS3603, BS3736; BS1511, BS2418, BS1017
respectively, dilution 1:200) overnight, PBS (two 10-min
rinses), goat anti-rabbit IgG serum biotinylated (Dako,
dilution 1:100) for 1h, PBS (two 10-min rinses), Vectastain
ABC Kit (Vector Laboratories, Burlingame, CA, USA) for
1h, and PBS (two 10-min rinses). As a negative control,
omission of the primary, secondary or tertiary antibodies
were used, and no immunostaining was observed. At the
last step, the immunoreaction was developed with 0.005%
diaminobenzidine (DAB; Sigma-Aldrich) and 0.003% H2O2.
All dilutions were made in PBS containing 0.2% Tween 20,
and incubations were made in a humid chamber at room
temperature.Finally,thesectionsweredehydrated,mounted,
and coverslipped.
Antibody characterization and speciﬁcity. According to
the technical information supplied by the manufacturer
(Bioworld Technology, MN, USA), the primary antibodies
used were raised against denatured mouse epitopes from
rabbit antiserum, and they were aﬃnity puriﬁed by chro-
matography using epitope-speciﬁc immunogen with purity
higher than 95% (by SDS-PAGE). Its speciﬁcity has been
assessed by Western blot; it recognizes a single-protein
band of approximately ≈86–90kD (β-catenin), ≈43–45kD
(p53), ≈26–28kD (BCL-2), ≈84–86kD(MLH1),and ≈270–
280kD(APC).Moreover,antibodieshavewidespeciescross-
reactivity and were used for demonstrating their expression
in mouse, rat, and human. Lesions were classiﬁed as posi-
tive for catenin-β/BCL-2/MLH1/APC if cytoplasmic/nuclear
staining was detected, and p53 was considered positive if
n u c l e a re x p r e s s i o nw a sd e t e c t e d .T w od i ﬀerent observers
evaluated individually and independently the experimental
group slides in a double-blind manner and achieved a high
levelofconcordance.Threesectionsofeachmousecolorectal
segment were coded and scored for lesions according to the
extent ulceration (0, not present and 1 present), severity of
lesions, hyperplasia, and area involved, graded as follow: 0,
normal; 1, mild; 2, moderate; 3, severe.
2.6. Imaging. The sections were photographed with an
Olympus microscope (BX50) equipped with a color digital
camera (DP10). The photographs were converted to gray
scale and adjusted for brightness and contrast with Corel
Draw (Corel, Ottawa, Canada), and the plates composed
with Corel Photo Paint.
2.7. Th1/Th2 Cytokine Proﬁle Detection. Quantitative detec-
tion of GM-CSF, IFN-γ,I L - 1 β,I L - 2 ,I L - 4 ,I L - 5 ,I L - 6 ,I L -
10, IL-17, and TNF-α was performed by using a FlowCy-
tomix Mouse Th1/Th2 10plex (BMS820FF) from Bender
MedSystems which allowed to measure multiple analytes
in a single 50 microliter aliquot of mice sera. In brief,
microparticle beads were dyed with diﬀering concentrations
of two ﬂuorophores to generate distinct bead sets. Each bead
set was coated with capture antibody speciﬁc for one analyte.
Captured analyte was detected using a biotinylated detection
antibody and streptavidin-phycoerythrin (S-PE). A FACScan
ﬂow cytometer from Becton Dickinson was used to acquire
samples. For calculation of results, the FlowCytomix Pro
Software (Bender MedSystems) was used.
3. Results
3.1. Treatment with FR91 Ameliorates Acute and
Chronic DSS-Induced Colitis
3.1.1. Pathological and Inﬂammatory Findings. The mice
that received repeated administrations of 2% DSS and
lower or absent levels of FR91 (groups 2 and 3) showed
bloody stools during the second half of the experiment,
(from the ﬁfth week onwards), whereas no such internal
inﬂammation feature was observed in the other mice
groups. Macroscopically, we have identiﬁed numerous gross
inﬂammatory polypoid lesions in mice of groups 2 (6/6;
100%) and 3 (5/6; 83.3%), mainly on the middle and
distal portions of the colorectal segment, and very few
were observed in group 4 (1/6; 16.6%). Remarkably, none
of the mice group 5 (DSS/20%FR91) showed any ulcer
formation in the colorectal segment analyzed, as well as
the treatment control mice group 1 (10%FR91) that was
also free of colitic ulcerations. These macroscopical obser-
vations were conﬁrmed by histological analysis of the
intestinal morphology emphasizing the alterations regarding
the integrity and inﬂammation of colonic mucosa and
submucosa,dysplasticepithelium,andthepresenceofulcers.
This histological examination of transverse sections staining
with H&E (Figure 2) showed ulcers with moderate-to-severe
morphological alterations (multifocal areas of inﬂamation in
the submucosa or ulcers that covered large mucosal areas),
mild-to-severe crypt hyperplasia (lining epithelium was two
to three times normal thickness, marked hypercromasia of
cells, and multiple crypts with arborizing pattern), epithelial
dysplasia (alteration in the diﬀerentiation of epithelial cells
that may progress to invasive carcinoma), and large aﬀected4 Journal of Biomedicine and Biotechnology
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Figure 2: Histological sections of three diﬀerent portions of the experimental mice colon to show histopathological lesions identiﬁed by
hematoxylin and eosin staining. (a–c) Transverse sections at three diﬀerent colorectal levels (proximal, middle, and distal) of mice group
1 treated with FR91 (10%). Note the absence of colonic lesions and the similar epithelial structures observed in normal control mice. (d–
f) Transverse sections at three diﬀerent colorectal levels of mice group 2 treated with DSS (2%) for 5 weeks. In each studied level, multiple
histopathologicallesionswereobserved,beingparticularlyclearthesevere-gradedysplasia(arrowheadsin(d)and(e))developedinthecolon
of mice from this group, together with aberrant crypts (arrow in (d)), adenomatous polyps (arrowhead in (f)), and incipient ulcerations
(arrow in (f)). (g–I) Transverse sections at three diﬀerent colorectal levels of mice group 3, with the administration of DSS (2%) for 5 weeks
and treated with FR-91 (5%). Although these three colonic levels show a low-grade dysplasia and some scattered mucosal ulcerations, the
structural histological pattern in general is functional. (j–l) Transverse sections at three diﬀerent colorectal levels of mice group 4, with the
administration of DSS (2%) for 5 weeks and treated with FR-91 (10%). This group showed a better colorectal histological organization than
that observed in group 3 although there are some mild-grade dysplastic crypts mainly at the distal segments. (m–o) Transverse sections at
three diﬀerent colorectal levels of mice group 5, with the administration of DSS (2%) for 5 weeks and treated with FR-91 (20%). These
sections show a normal epithelial organization, with well-diﬀerentiated cryptal cells and no atypical lesion features. Scale bar: 100μm.
areas of crypt loss. However, severity of these colorectal
lesions diﬀered signiﬁcantly among mice groups, being the
mice group 2 (DSS) the one with a high severity level,
while the mice group 3 (DSS/5%FR91) showed a mild-to-
moderate severe level, and the mice group 4 (DSS/10%FR91)
presented a few mild scattered lesions. No colitis character-
istic lesions were observed in the colorectal segment of mice
group 5 (DSS/20%FR91) or in the treatment control mice
group 1 (10%FR91), (Figure 2), as described previously in
the macroscopical exam. Histological scoring data obtained
from the colorectal lesions examination are presented in
Table 1.
3.1.2. Immunohistochemistry of Catenin-β, p53, BCL-2,
MLH1, and APC. Immunohistochemical techniques used
to identify cell markers of the colorectal lesions showedJournal of Biomedicine and Biotechnology 5
Table 1: Histological scores for the colorectal lesions observed in ﬁve experimental mice groups. Data are expressed as mean ± standard
deviation.
n Colon segment aﬀected Extent
ulceration Severity Hyperplasia Area
involved Total score
Group 1 4 Normal 0 0 0 0 0
Group 2 4 Proximal, middle, distal 1 2.6 ±0.23 2.8 ±0.43 3.2 ±0.33 9.6 ±0.99
Group 3 6 Middle, distal 0 1.5 ±0.18 2.7 ±0.31 2.4 ±0.17 6.6 ±0.66
Group 4 6 Middle, distal 0 0.6 ±0.14 1.1 ±0.13 0.9 ±0.20 2.6 ±0.47
Group 5 6 Normal 0 0 0 0 0
expression of Catenin-β (cellular adhesion regulator), BCL-2
(apoptotic regulator), MLH1 (DNA-mismatch repair), APC,
and p53 (tumour suppressor proteins) in all colonic mice
lesions observed and described above. Catenin-β antibody
detected endogenous expression levels of catenin-β protein
mainly in the cytoplasm of adenocarcinoma and dysplastic
cells. Intense catenin-β expression was observed in the
proximal and middle (Figure 3(f)) colon of mice group 2
(DSS) whereas a moderate-to-intense immunoreactivity was
also observed in the colorectal segments (Figure 3(k))o f
mice group 3 (DSS/5%FR91). Catenin-β-immunoreactive
(-ir) cells were localized in the dysplastic criptal cells and
adenocarcinoma cells, at the internal criptal layers (Figures
3(f) and 3(k)). Colorectal portions of mice groups 1, 4, and
5 showed a weak or absent catenin-β-positive reaction in
their cryptal cells (Figures 3(a), 3(p),a n d3(u)), considered
as catenin-β cellular basal expression. BCL-2-ir and p53-ir
cells were observed at colorectal portions of mice groups 2
(Figures3(g)and3(j))and3(Figures3(l)and3(o)),showing
an intense staining in adenocarcinoma and cryptal cells, par-
t i c u l a r l ys t r o n gi nm i c eg r o u p2 .I m m u n o r e a c t i v i t yt oB C L - 2
and p53 was absent in colorectal section of mice groups 1, 4,
and 5 studied (Figures 3(b), 3(q), 3(v), 3(e), 3(t),a n d
3(y)). Strong staining MLH1-ir cells were observed at color-
ectal segments of mice groups 2 (Figure 3(h))a n d3
(Figure 3(m)), showing an intense staining in adenocar-
cinoma and cryptal cells of the dysplastic epithelium,
particularly intense in mice group 2. MLH1-ir cells were
absentincolorectalsectionofmicegroups1,4,and5studied
(Figures 3(c), 3(r),a n d3(w)). APC immunoreactivity was
intensely observed in all colorectal portions of mice groups
2( Figure 3(i))a n d3( Figure 3(n)) although cryptal cells
of mice group 2 showed a stronger positivity. Colorectal
portions of mice groups 1, 4, and 5 showed a weak APC
immunoreactivity in their cryptal cells (Figures 3(d), 3(s),
and 3(x)).
The incidence of colon lesions showed by these cell
markers in the group 5 was 8.2% (±4%), whereas it was
38.2% (±6%), 33.3% (±6%), and 20.4% (±3%) in groups
2, 3, and 4, respectively (see Figures 4 and 5). Similar
histological incidence was observed in mice group 5 when
compared with negative control group 1 (7.8%, ±2%). Two-
factor ANOVA of data for each immunohistological markers
in the colorectal portion showed signiﬁcant diﬀerences
amongexperimentalgroups1/5and2/3/4,(Figure 5).Group
5 was the most resistant mice group to DSS-induced lessions
in the colorectal portion, as indicated by the lowest value for
each marker, similar to that observed in the control group
1. Groups 2, 3, and 4 showed more susceptibility to DSS-
induced lessions, consistent with high values. Signiﬁcant
group diﬀerences were found between group 1/5 and 2/3/4
in DSS susceptibility, being correlated with diﬀerences in the
FR91 mean consumption per group.
3.1.3. DSS Production of Inﬂammatory Cytokines. We next
considered potential mechanisms which might underlie the
colitis exhibited by DSS treatment and the eﬀect of FR-91 in
the treated mice groups. As shown in Table 2, DSS treatment
increased only the production of IFN-γ proinﬂammatory
cytokine. No signiﬁcant changes were detected in IL-1β,
TNF-α, IL-6, IL-10, and IL-17 in both treated and untreated
groups.
4. Discussion
More than 20,000 bioactive compounds synthesized by
microorganisms have been identiﬁed, and over 10,000 of
these secondary metabolites are produced by actinomycets,
representing 45% of all bioactive metabolites discovered [8].
Among actinomycetes, around 8,000 compounds are synthe-
sized by Streptomyces species [8]. The main function of these
compounds is antibiotic activity. In addition, many of these
compounds, such as anthracyclines (aclarubicin, dauno-
mycin, and doxorubicin), peptides (bleomycin and actino-
mycin D), aureolic acids (mithramycin), enediynes (neo-
carzinostatin), antimetabolites (pentostatin), carzinophilin,
mitomycins, and others [9, 10] have also been tested for the
inhibition of chemically induced carcinogenesis in both in
vitro and in vivo animal models [11].
In the present study, we investigated the eﬀect of FR91,
a standardized lysate of microbial cells belonging to the
Bacillus genus which has been previously shown to have
signiﬁcant immunomodulatory eﬀects tested on human
tumor cell lines [12], on colonic inﬂammation induced by
8-week exposure of 2% DSS in the drinking water and,
in particular, whether FR91 aﬀects colorectal inﬂammation.
We found that the six-week treatment resulted in a slightly
reduction of colorectal lesions at lower dosis (5% FR91) and
a moderate-to-complete reduction at higher dosis (10–20%
FR91). Moreover, histopathological data showed that FR91
hasnopathologicaleﬀectonthemorphologicalorganization
of the mice colon tissues, as observed when administering6 Journal of Biomedicine and Biotechnology
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Figure 3: Immunohistochemistry of colorectal pathological markers in diﬀerent transverse section of colon in mice. (a–e) Details of
transverse sections at middle and distal colorectal levels of mice group 1, showing scarce immunoreactivity to Catenin-β, p53 or absence
of BCL-2, MLH-1, and APC. Note that these sections also show a normal epithelial organization with well-diﬀerentiated cryptal cells. (f–j)
Details of transverse colon sections of mice group 2, showing intense immunoreactivity to the cell markers studied. Note the numerous
immunoreactive cells (arrows in (f–i)) and their massive location at the diﬀerent pathological lesions, such as severe-grade dysplasia
(arrowheadsin(f)),polyps(arrowheadin(j)),andadenomas.(k–o)Detailsoftransversecolonsectionsofmicegroup3,showingmoderate-
to-scarceimmunoreactivitytothecellmarkersinthecolorectalsegments.NotesomeimmunoreactivecellstoCatenin-β (arrowheadsin(k)),
MLH-1 (arrow in (m)), APC (arrows in (n)), and p53 (arrows in (o)). (p–t) and (u–y). Details of transverse colon sections of mice group
4 (p–t) and goup 5 (u–y), showing absence or basal (arrows in (s) and (x)) immunoreactivity to the cell markers in the colorectal segments
studied. Scale bar: 100μm.Journal of Biomedicine and Biotechnology 7
Table 2: Levels of IL-1α (pg/mL), IL-2 (pg/mL), IL-5 (pg/mL) IL-6 (pg/mL), IL-10 (pg/mL), IFN-γ (pg/mL), TNF-α (pg/mL), GM-CSF
(pg/mL), IL-4 (pg/mL) and IL-17 (pg/mL) in mice serum samples. Data are expressed as mean ± standard deviation.
IL-1α IL-2 IL-5 IL-6 IL-10 IFN- γ TNF- α GM-CSF IL-4 IL-17
FR-91 0 0 20 ±1.52 5 ±2.50 0 07 8 ±3.80 0
DSS 0 0 78 ±4.54 8 ±5.4 175 ±4.5 363 ±13.4 125 ±9.70 01 ±0.2
5% 0 55 ±3.37 8 ±3.95 3 ±7.69 6 ±10.1 0000 2 4 ±2.9
10% 0 34 ±3.83 7 ±2.1 149 ±99 7 ±8.60 04 1 ±5.70 1 2 ±1.7
20% 0 0 38 ±3.94 7 ±7.25 5 ±5.81 5 ±2.107 5 ±4.40 1 7 ±2.5
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Figure 4: Image analysis of colorectal damaged area observed in
the three portions of the colon in each experimental mice group.
Thequantiﬁcationinpixelsoftheimmunoreactiveareaaﬀectedwas
performed by a software analysis of the colorectal sections studied.
Group 5 showed a signiﬁcantly diﬀerence (P<0.05) to the other
treatment groups (3 and 4).
FR91 alone during the entire experimental study. The data
obtainedsuggeststhatFR91maybeanimportantchemopre-
ventive agent against intestinal inﬂammation in mice colon.
In our experiment, we induced a wide range of colorectal
lesions to better evaluate the eﬀects of an anticancer agent
(FR91) on chronic ulcerative colitis in mice. The repeated
administration of DSS as an inductor of ulcerative lesions
in mice models of colitis was extensively reported [13–
18], being essential in advancing our understanding of the
complex interactions between the environment, genetics,
and epithelial barrier dysfunction in the human-related
InﬂammatoryBowelDisease[19–22].Inthisstudy,theuseof
DSS in drinking water during ﬁve weeks resulted in epithelial
damage and a robust inﬂammatory response, obtaining a
valid mice model acute injury colon to test an eight-week
treatment with FR91, as reported in previous studies [23–
26].Ourresultsdemonstratedthattheoptimaldoseresponse
was the 20% FR91 concentration tested in mice group
5, where no histological alterations or mild lesions were
observed. Routinary histological staining [20, 23, 24, 27]a n d
pretumoral cell markers [18, 20, 23, 28] used to evaluate the
severity of lesions conﬁrmed the protective eﬀect of FR91
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Figure 5: Image analysis of the mean value of colorectal damage
area marked by immunoreactivity in mice groups. Group 5 showed
a signiﬁcantly diﬀerence (P<0.05) to the other treatment groups
(3 and 4), and a similar mean value when compared with negative
c o n t r o l( g r o u p1 ) .
against the inﬂammation eﬀect of DSS. These pretumoral
cell markers such as APC, p53, MLH, BCL-2, Catenin-β,
and cytokines, among others, take part in the molecular
pathogenesis pathway of chronical colorectal inﬂammation
that has been reported to derive at further stages in the
development of sporadic colorectal carcinoma and colitis-
associatedcoloncancer[22,29–31].Thepresentresultsshow
the same signiﬁcant interaction of these genetic markers in
the pathologic characterization of the DSS-induced lessions
observed. As reported in similar studies, a dosis-dependent
eﬀect is normally associated with the chemoprevention
process in DSS-induced colitis [25, 26]. Therefore, we tested
other lower FR91 concentrations in drinking water, obtain-
ing gradual colorectal lesions as the FR91 concentrations
decreased. Moreover, we also tested the eﬀects of FR91 in
mice during a large period of time (8 weeks), obtaining
similar histological results as the nontreated mice, which
indicates a chemopreventive action against carcinogenesis
without interfering with healthy epithelial structures of the
mice colon.
Chemopreventive eﬀects of a wide range of compounds
on colonic tumors induced in mice have been reported
previously, such as organosulfur compounds [25], N acetyl-
cysteine [32], tetrandrine [33], phytosteryl ferulates [29],8 Journal of Biomedicine and Biotechnology
and dibenzoylmethane derivatives [34]. The DSS-induced
lessions reported in these studies are similar to that observed
in the preset work, where generally predominated in the
midcolon [7, 35] and distal [24, 36] intestinal portions.
These particular locations have been attributed to several
factors such as the selective uptake of DSS in certain colonic
portions, the presence of weak intestinal barrier regions, and
diﬀerent distribution of macrophages populations along the
mice colon.
Alterations in the production of many cytokines have
been observed in patients with IBD [37]. Although the real
impactoftheseﬁndingsinthepathogenesisofIBDremainsa
controversial issue, as it is unclear whether they are primary
or secondary factors involved in the regulation of the mu-
cosal intestinal immune system, they can be considered as
markers in the diﬀerentiation of groups of patients. In active
IBD, an unbalance between regulatory and eﬀector cells
has been described, which mainly involves eﬀector T cells
(Th1 and Th2) and regulatory T cells (Tregs, Th3). CD
is associated with a Th1 T-cell cytokine proﬁle, including
IFN-γ,T N F - α, and IL-12, whereas UC is associated with a
modiﬁed Th2 type response cytokine proﬁle including IL-15
and IL-10 [38]. In addition, these ﬁndings have been recently
complemented by the discovery of the IL-23/IL-17 axis,
that is, part of the eﬀector T-cell immunological response
and seems to be involved in IBD. Levels of expression of
IL-23 and IL-17 are increased in patients with active IBD
[39].
Although speciﬁc determination of the FR91 metabolic
action in the colitis prevention and treatment will require
further investigations, we showed that FR91 prevented ul-
cerative lesions in mice models of colitis, inhibiting the
development of colorectal tumors. FR91 has proved to be an
interesting and promising investigational agent for studying
chemoprevention of carcinogenesis.
Abbreviations
CL: Crypt of Lieberkuhn
d: Distal portion of the colon
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